¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦49Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦9Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 1 : 2023-06-15

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

Á¦49Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦9Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 1 : 2023-06-15
±³À°ÀÏÀÚ : 2023-06-15
±³À°Àå¼Ò : ¼­¿ï·Ôµ¥È£ÅÚ

±³À°ÁÖÁ¦ : Á¦49Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦9Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 1

ÁÖÃÖ±â°ü : ´ëÇѾÏÇÐȸ
´ã´çÀÚ : ÀÌÈñ¿¬
¿¬¶ôó : 02-792-1486  

À̸ÞÀÏ : cancer2@kams.or.kr

±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢ÀÇÇаú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú, ¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈ­ÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ¾à¸®ÇÐ

Âü¼®¿¹»óÀÎ : 1500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 18 ½Ã°£ 10ºÐ

¼¼ºÎ¼ö°­·á : 200,000¿ø  

ºñ°í "1. ȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 10¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 5¸¸¿ø / 3) ¾÷ü ¹× ¿¬±¸¼Ò: 15¸¸¿ø

2. ºñȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 15¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 7¸¸¿ø / 3) ¾÷ü ¹× ¿¬±¸¼Ò: 20¸¸¿ø"


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal A 09:00~09:25 scMultiomics (RNA + ATAC) for 'acquired epithelial WNT secretion drives niche independence of developing gastric cancer¡¯ ÀÌÈñŹ(±âÃÊ°úÇבּ¸¿ø(IBS))

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal A 09:25~09:50 Spatial transcriptome analysis for tumor microenvironment ¹Ú¿õ¾ç(»ï¼ºÀ¯Àüü¿¬±¸¼Ò)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal A 09:50~10:15 Spatial transcriptomics and epitranscriptomics in cancer microniches ÀÌÃæ¿ø(¼­¿ï´ë)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal A 10:15~10:40 Single cell genomics approach to identify immune determinants for PD-1 inhibitors ±èÇý·Ã(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal B 09:00~09:00 Current status of cancer burden in Korea Á¤±Ô¿ø(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal B 09:30~09:30 Genetic and environmental determinants for cancer and the role of early detection ½Å¾Ö¼±(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal B 10:00~10:30 Harnessing multimodal cancer signatures in circulating tumor DNA for earlier cancer detection ¹æµÎÈñ(¿¬¼¼´ë)

±³À°½Ã°£ 06¿ù 15ÀÏ Sapphire A 09:00~09:25 Clinical application of circulating tumor DNA: Monitoring and genetic evaluation Nobuaki Matsubara(National Cancer Center Hospital East, Japan)

±³À°½Ã°£ 06¿ù 15ÀÏ Sapphire A 09:25~09:50 Monitoring of minimal residual disease (tumor burden) using circulating tumor DNA Yingchi Zhang(Chinese Academy of Medical Sciences and Peking Union Medical College, China)

±³À°½Ã°£ 06¿ù 15ÀÏ Sapphire A 09:50~10:15 Monitoring and prediction for clinical outcomes after irradiation ³ëÀç¸í(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 06¿ù 15ÀÏ Sapphire A 10:15~10:40 Disease evaluation or monitoring using extracellualr vesicle ±èÇÑ»ó(¿¬¼¼ÀÇ´ë)

ÈÞ½Ä 06¿ù 15ÀÏ 10:40~11:00 ÈÞ½Ä ()

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal 11:00~11:40 Targeting tumor-infiltrating Tregs as a cancer immunotherapy Shimon Sakaguchi(Osaka University, Japan)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal 11:40~12:20 The seven deadly hallmarks of pancreatic cancer David Tuveson(Cold Spring Harbor Laboratory Cancer Center, USA)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal A 12:20~13:00 Blossom women's more TOMMOROWs with pembrolizumab ±è°Ç¹Î(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal B 12:20~12:40 Illuminating the path forward in early stage NSCLC: Unmet needs and the evolving treatment landscape (IMP010)  ÀÓ¼±¹Î(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 06¿ù 15ÀÏ Sapphire A 12:20~12:40 Clinical considerations for ribociclib treatment in HR+HER2- mBC patients ¿øÇý¼º(ÀÇÁ¤ºÎ¼º¸ðº´¿ø)

ÈÞ½Ä 06¿ù 15ÀÏ 13:00~13:20 ÈÞ½Ä ()

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal A 13:20~13:45 The basics of antibody engineering ÀÌâÇÑ(¼­¿ï´ë)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal A 13:45~14:10 Recent advances of antibody-drug conjugates for clinical applications Chul Kim(Georgetown University, USA)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal A 14:10~14:35 Resistance to antibody-drug conjugates Á¤Ã¶¿õ(·¹ÄÚÄ·¹ÙÀÌ¿À)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal A 14:35~15:00 Site-selective antibody-drug conjugate for cancer therapy Á¤»óÀü(¼º±Õ°ü´ë)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal B 13:20~13:45 TIME-controlled cancer immunotherapy ÀÓ¿ëÅÃ(¼º±Õ°ü´ë)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal B 13:45~14:10 Novel technologies of CAR-T cell therapy for solid cancers Koji Tamada(Yamaguchi University, Japan)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal B 14:10~14:35 Antibody-mediated T-cell epitope delivery into target tumor cells for cancer immunotherapy ±è¿ë¼º(¾ÆÁÖ´ë)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal B 14:35~15:00 Treg activation mechanisms in tumor microenvironment and application to immunotherapy Shohei Koyama(National Cancer Center East, Japan)

±³À°½Ã°£ 06¿ù 15ÀÏ Sapphire A 13:20~13:45 Updates on radiotherapy for oligometastatic and oligoprogressive cancer C. Jillian Tsai(Princess Margaret Cancer Centre, University Health Network, Canada)

±³À°½Ã°£ 06¿ù 15ÀÏ Sapphire A 13:45~14:03 Customized RT in oligometastasis Á¶¿ø°æ(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 06¿ù 15ÀÏ Sapphire A 14:03~14:21 Update on surgical management for oligometastasis ¾öÁØ¿ø(°í·ÁÀÇ´ë)

±³À°½Ã°£ 06¿ù 15ÀÏ Sapphire A 14:21~14:39 Issues of care for oligometastasis in clinical practice À̸í¾Æ(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 06¿ù 15ÀÏ Sapphire A 14:39~15:00 Barriers in oligometastasis care, an RO perspective ÁöÀDZÔ(¼­¿ïÀÇ´ë)

ÈÞ½Ä 06¿ù 15ÀÏ 15:00~15:20 ÈÞ½Ä ()

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal A 15:20~15:45 NANOG is a main driver of therapy-refractory evolution of tumor cells during immunotherapy ±èÅ¿ì(°í·ÁÀÇ´ë)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal A 15:45~16:10 Elucidation of sensitivity and resistance factors to cancer immunotherapy using artificial intelligence À̼¼ÈÆ(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal A 16:10~16:35 Blood-derived umor-associated macrophages contribute to antitumor immunity against glioblastoma ÀÌÈï±Ô(KAIST)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal A 16:35~17:00 Tumor hypoxia as a target for immunotherapy ¹Ú°æÈ­(°í·ÁÀÇ´ë)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal B 15:20~15:45 Unravelling cancer ecosystem at single-cell resolution ¹ÚÁ¾Àº(KAIST)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal B 15:45~16:10 Stromal reprograming in fibrous tumor Takatsugu Ishimoto(Kumamoto University, Japan)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal B 16:10~16:35 Epigenetic regulation of transcriptional heterogeneity in pancreatic cancer ³ëÀç¼®(¿¬¼¼´ë)

±³À°½Ã°£ 06¿ù 15ÀÏ Crystal B 16:35~17:00 Resolving transcriptional dynamics for single cell and spatial transcriptomics of gastric cancers ±èŹÎ.(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 06¿ù 15ÀÏ Sapphire A 15:20~15:45 Recent advances in CAR-T cell engineering for solid tumors ÇÑÃæ¿ë(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 06¿ù 15ÀÏ Sapphire A 15:45~16:10 Current status and perspective of CAR-T cell therapy trials À±´öÇö(¿ï»êÀÇ´ë)

±³À°½Ã°£ 06¿ù 15ÀÏ Sapphire A 16:10~16:35 Nanomedicine approaches for in vivo gene editing and therapy Á¤ÇöÁ¤(KAIST)

±³À°½Ã°£ 06¿ù 15ÀÏ Sapphire A 16:35~17:00 Platform development for CAR-NK therapy: Gene design and delivery ±èŵ· (Çѱ¹»ý¸í°øÇבּ¸¿ø)

±³À°½Ã°£ 06¿ù 15ÀÏ Sapphire B 15:20~15:45 Çѱ¹ º¸°ÇÀÇ·áÁ¤º¸ ¹ßÀü¹æÇâ º¯³²¼ö(º¸°ÇÀÇ·áÁ¤º¸¿ø)

±³À°½Ã°£ 06¿ù 15ÀÏ Sapphire B 15:45~16:10 ¾Ïµ¥ÀÌÅÍ ±¸Ãà°ú È°¿ëü°è: ¾Ï ÀÓ»ó³×Æ®¿öÅ© ±¸Ãà»ç¾÷(K-CURE)À» Áß½ÉÀ¸·Î Ãֱͼ±(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 06¿ù 15ÀÏ Sapphire B 16:10~16:35 ±¸ÃàµÈ µ¥ÀÌÅÍÇ÷§Æû ³»¿ë (CODA ¹× ÀÌ°üµÈ K_MASTER È°¿ë ºÎºÐ µî) ¹ÚÇö¿µ(Áúº´°ü¸®Ã»)

±³À°½Ã°£ 06¿ù 15ÀÏ Sapphire B 16:35~17:00 ±¹°¡¹ÙÀÌ¿Àµ¥ÀÌÅͽºÅ×ÀÌ¼Ç ¼Ò°³ ±è¼±¿µ(Çѱ¹»ý¸í°øÇבּ¸¿ø)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦49Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦9Â÷ ±¹Á¦¾ÏÄÁÆÛ·±½º 1 : 2023-06-15""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑ»êºÎÀΰúÇÐȸ ´ë±¸Áöȸ ¿¬¼ö°­Á : 2023-06-15
´ÙÀ½±Û 2023³âµµ ´ëÇÑÁø´Ü°Ë»çÀÇÇаú°³¿øÀÇ»çȸ Çмú´ëȸ : 2023-06-15
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 7 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 12 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 7 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 4 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 7 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 7 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 3 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 1 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 2 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 4 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 5 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 3 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 4 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 4 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 7 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷